Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 350 of 427 entries
View as:

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04089527 Org: User:
Start: 10/24/19 End: 10/25/21 Due: 10/25/22

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT04951778 Org: User:
Start: 12/02/21 End: 05/05/27 Due: 05/05/28

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02510937 Org: User:
Start: 08/05/15 End: 02/06/17 Due: 02/06/18

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT02641002 Org: User:
Start: 03/01/16 End: 07/18/18 Due: 07/18/19

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

Phase: N/A Priority: Normal
NCT ID: NCT06411730 Org: User:
Start: 05/31/24 End: 10/28/24 Due: 10/28/25

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT01647516 Org: User:
Start: 12/26/12 End: 08/30/19 Due: 08/30/20

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

Phase: N/A Priority: Normal
NCT ID: NCT01996865 Org: User:
Start: 04/01/14 End: 09/17/24 Due: 09/17/25

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00045786 Org: User:
Start: 10/31/01 End: 11/30/03 Due: 11/30/04

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Phase: N/A Priority: Normal
NCT ID: NCT00875667 Org: User:
Start: 04/30/09 End: 10/09/18 Due: 10/09/19

A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR

Phase: N/A Priority: Normal
NCT ID: NCT02387879 Org: User:
Start: 12/25/13 End: 12/31/22 Due: 12/31/23

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Phase: N/A Priority: Normal
NCT ID: NCT00910910 Org: User:
Start: 10/13/09 End: 05/09/18 Due: 05/09/19

Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea

Phase: N/A Priority: Normal
NCT ID: NCT03288974 Org: User:
Start: 12/28/17 End: 11/16/23 Due: 11/16/24

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01997840 Org: User:
Start: 03/01/14 End: 02/29/24 Due: 02/28/25

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase: N/A Priority: Normal
NCT ID: NCT06232707 Org: User:
Start: 05/03/24 End: 09/21/30 Due: 09/21/31

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04975399 Org: User:
Start: 10/05/21 End: 06/18/24 Due: 06/18/25

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

Phase: N/A Priority: Normal
NCT ID: NCT04639115 Org: User:
Start: 12/18/20 End: 04/06/22 Due: 04/06/23

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT01522547 Org: User:
Start: 08/01/07 End: 12/01/13 Due: 12/01/14

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00528983 Org: User:
Start: 09/11/07 End: 04/05/16 Due: 04/05/17

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02620800 Org: User:
Start: 01/18/16 End: 10/29/18 Due: 10/29/19

Observational Study of Quality of Live in Patients With Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02342847 Org: User:
Start: 12/10/14 End: 11/16/18 Due: 11/16/19

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03983239 Org: User:
Start: 06/21/19 End: 11/06/19 Due: 11/06/20

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT02775903 Org: User:
Start: 06/03/16 End: 12/27/21 Due: 12/27/22

A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04702464 Org: User:
Start: 01/12/21 End: 05/13/21 Due: 05/13/22

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03142191 Org: User:
Start: 07/26/17 End: 12/24/21 Due: 12/24/22

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Phase: N/A Priority: Normal
NCT ID: NCT04446650 Org: User:
Start: 10/12/20 End: 10/31/25 Due: 10/31/26